Product Description
Dydrogesterone is an orally active progestogen which acts directly on the uterus, producing a complete secretory endometrium in an estrogen-primed uterus. At therapeutic levels, dydrogesterone has no contraceptive effect as it does not inhibit or interfere with ovulation or the corpus luteum. Furthermore, dydrogesterone is non-androgenic, non-estrogenic, non-corticoid, non-anabolic and is not excreted as pregnanediol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dydrogesterone#section=Pharmacology-and-Biochemistry)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company Founding Year: 1888
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Abortion, Spontaneous|Pregnancy Outcomes|Obstetric Labor, Premature|Menopause|Genital Diseases, Female|Infertility, Male|Infertility, Female|Fetal Death|Endometrial Cancer|Leiomyoma|Abortion, Habitual|Abortion, Threatened|Gynatresia|Myofibroma|Embryo Loss|Infertility|Multiple Sclerosis
Phase 3: Infertility, Male|Menopause|Infertility, Female|Pregnancy Outcomes|Abortion, Habitual|Abortion, Spontaneous|Menorrhagia|Abortion, Threatened|Infertility|Pregnancy, Ovarian|Vaginal Cancer|Follicular Cyst|Vitamin A Deficiency|Weight Gain|Weight Loss|Endometrial Cancer|Pregnancy, Abdominal|Hypertension, Renal|Kidney Diseases|Stroke|Obstetric Labor, Premature|Ovarian Cysts|Muscle Cancer|Acute Respiratory Distress Syndrome|Protein Deficiency|Genital Cancer, Female|Male Breast Cancer|Liver Cancer|Bone Cancer|Pelvic Cancer|Uterine Cancer|Drug Overdose|Body Weight Changes|Vascular Cancer
Phase 2: Anorexia
Phase 1: Pregnancy, Ovarian|Pregnancy Outcomes|Menopause|Follicular Cyst|Polycystic Ovary Syndrome|Hyperandrogenism|Ovarian Cysts|Conduct Disorder|Infertility|Gynatresia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500096050 |
Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women based on fNIRS detection | N/A |
Not yet recruiting |
Dementia |
2029-12-01 |
|||
ChiCTR2500113652 |
ChiCTR2500113652 | N/A |
Not yet recruiting |
Pregnancy Outcomes |
2028-12-31 |
|||
ChiCTR2500103211 |
ChiCTR2500103211 | N/A |
Not yet recruiting |
Endometriosis |
2028-01-31 |
|||
ChiCTR2600118421 |
ChiCTR2600118421 | N/A |
Not yet recruiting |
Abortion, Spontaneous |
2028-01-01 |
|||
ChiCTR2400094539 |
ChiCTR2400094539 | N/A |
Not yet recruiting |
Infertility |
2027-12-31 |
|||
ChiCTR2500110611 |
ChiCTR2500110611 | N/A |
Not yet recruiting |
Infertility |
2027-10-01 |
|||
ChiCTR2400091369 |
ChiCTR2400091369 | N/A |
Not yet recruiting |
Injuries/wounds Unspecified |
2027-06-30 |
|||
NCT05847283 |
DPOS | N/A |
Recruiting |
Pregnancy Outcomes|Obstetric Labor, Premature|Abortion, Threatened|Pregnancy, Ovarian|Acute Respiratory Distress Syndrome |
2027-05-31 |
2024-11-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
ChiCTR2500098020 |
ChiCTR2500098020 | N/A |
Recruiting |
Infertility |
2027-02-26 |
|||
ChiCTR2400084571 |
ChiCTR2400084571 | N/A |
Not yet recruiting |
Infertility |
2026-12-31 |
2024-05-22 |
Treatments |
|
ChiCTR2400079652 |
ChiCTR2400079652 | N/A |
Not yet recruiting |
Depressive Disorder |
2026-11-30 |
2024-01-11 |
Treatments |
|
ACTRN12621000439842p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Leukemia |
2026-08-03 |
|||
NCT06952296 |
Daisy | N/A |
Not yet recruiting |
Endometriosis |
2026-06-30 |
2025-08-27 |
Primary Endpoints|Treatments |
|
ChiCTR2400087131 |
ChiCTR2400087131 | N/A |
Not yet recruiting |
Pregnancy Outcomes |
2026-06-01 |
2024-07-22 |
Treatments |
|
ChiCTR2400089666 |
ChiCTR2400089666 | N/A |
/Completed |
Periodontal Diseases|Immune Complex Diseases|Chronic Periodontitis|Tooth Loss|Inflammation|Periodontal Pocket |
2026-04-30 |
|||
CTR20254733 |
CTR20254733 | N/A |
Completed |
Healthy Volunteers |
2026-02-09 |
2026-02-15 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2300074428 |
ChiCTR2300074428 | N/A |
Not yet recruiting |
Endometrial Hyperplasia |
2026-01-19 |
2023-08-08 |
Treatments |
|
NCT06378268 |
ProGanOS | N/A |
Recruiting |
Follicular Cyst|Pregnancy Outcomes|Ovarian Cysts|Pregnancy, Ovarian |
2025-12-31 |
2024-04-27 |
||
CTR20252416 |
CTR20252416 | N/A |
Completed |
Menopause |
2025-12-08 |
2025-12-21 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252417 |
CTR20252417 | N/A |
Completed |
Menopause |
2025-11-04 |
2025-11-23 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2300077340 |
ChiCTR2300077340 | N/A |
Recruiting |
Polycystic Ovary Syndrome |
2025-11-01 |
2024-05-26 |
Treatments |
|
CTR20252451 |
CTR20252451 | N/A |
Completed |
Menopause |
2025-10-08 |
2025-10-28 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT03859921 |
UW 18-594 | P3 |
Recruiting |
Infertility |
2025-12-30 |
2025-06-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
2023-509919-89-00 |
2023-509919-89-00 | P4 |
Recruiting |
Infertility, Male|Infertility, Female |
2027-10-01 |
2025-05-02 |
Treatments |
|
2024-513998-48-00 |
CS-10459 | P4 |
Recruiting |
Unknown |
2026-06-30 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/10/2023 |
News Article |
Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc. |
|
10/03/2023 |
News Article |
Dydrogesterone API Market Is Likely to Experience Incredible Growth in Near Future By 2029 |
|
10/03/2023 |
News Article |
Oral Dydrogesterone Market Size, Trends & Opportunities, Research Report 2023 -2031 |
|
09/26/2023 |
News Article |
Single Axis Gyroscope Market Latest Trends and Growing Business Opportunities 2023 to 2029- TDK , Murata Manufacturing , TE Connectivity , Analog Devices |
